Dr. Reema Patel, MD
Claim this profileUniversity of Kentucky/Markey Cancer Center
Studies Adenocarcinoma
Studies Pancreatic Cancer
8 reported clinical trials
18 drugs studied
Area of expertise
1Adenocarcinoma
Stage IV
MSLN positive
HER2 negative
2Pancreatic Cancer
Stage IV
MSLN positive
Affiliated Hospitals
Clinical Trials Reema Patel, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy + Immunotherapy
for Mesothelioma
This phase II trial compares the usual treatment alone to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Recruiting1 award Phase 236 criteria
More about Reema Patel, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Reema Patel, MD has experience with
- Nivolumab
- Atezolizumab
- Placebo
- BXQ-350
- Ipilimumab
- Anetumab Ravtansine
Breakdown of trials Reema Patel, MD has run
Adenocarcinoma
Pancreatic Cancer
Neuropathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Reema Patel, MD specialize in?
Reema Patel, MD focuses on Adenocarcinoma and Pancreatic Cancer. In particular, much of their work with Adenocarcinoma has involved Stage IV patients, or patients who are MSLN positive.
Is Reema Patel, MD currently recruiting for clinical trials?
Yes, Reema Patel, MD is currently recruiting for 5 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Reema Patel, MD has studied deeply?
Yes, Reema Patel, MD has studied treatments such as Nivolumab, Atezolizumab, Placebo.
What is the best way to schedule an appointment with Reema Patel, MD?
Apply for one of the trials that Reema Patel, MD is conducting.
What is the office address of Reema Patel, MD?
The office of Reema Patel, MD is located at: University of Kentucky/Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky/Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.